Alaide Chieffo

List of Publications by Year
in descending order

394 papers	30,697 citations	7568 77 h-index	5539 163 g-index
406 all docs	406 docs citations	406 times ranked	18331 citing authors

#	Article	IF	Citations
1	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
2	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
3	Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents. JAMA - Journal of the American Medical Association, 2005, 293, 2126.	7.4	2,769
4	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	13.7	679
5	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
6	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, The, 2021, 397, 2385-2438.	13.7	530
7	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	2.8	445
8	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation, 2007, 116, 745-754.	1.6	430
9	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
10	Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2014, 64, 2086-2097.	2.8	388
11	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal, 2020, 41, 3504-3520.	2.2	385
12	ST-Elevation Myocardial Infarction in Patients With COVID-19. Circulation, 2020, 141, 2113-2116.	1.6	376
13	Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main. Circulation, 2005, 111, 791-795.	1.6	358
14	Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique. Journal of the American College of Cardiology, 2005, 46, 613-620.	2.8	320
15	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	2.8	319
16	Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis. Circulation, 2006, 113, 2542-2547.	1.6	287
17	In-stent restenosis in small coronary arteries. Journal of the American College of Cardiology, 2002, 40, 403-409.	2.8	244
18	Treating chronic total occlusions using subintimal tracking and reentry: The STAR Technique. Catheterization and Cardiovascular Interventions, 2005, 64, 407-411.	1.7	243

#	Article	IF	Citations
19	Modified T-stenting technique with crushing for bifurcation lesions: Immediate results and 30-day outcome. Catheterization and Cardiovascular Interventions, 2003, 60, 145-151.	1.7	237
20	Long-Term Outcomes After Stenting of Bifurcation Lesions With the â€œCrushâ€•Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	2.8	228
21	Novel Approaches for Preventing or Limiting Events (Naples) II Trial. Journal of the American College of Cardiology, 2009, 54, 2157-2163.	2.8	223
22	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
23	Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention, 2014, 10, 545-560.	3.2	213
24	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
25	Incidence, Predictors, and Implications of Access Site Complications With Transfemoral Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2012, 110, 1361-1367.	1.6	210
26	Results and Long-Term Predictors of Adverse Clinical Events After Elective Percutaneous Interventions on Unprotected Left Main Coronary Artery. Circulation, 2002, 106, 698-702.	1.6	199
27	First Clinical Experience With a Paclitaxel Derivateâ€“Eluting Polymer Stent System Implantation for In-Stent Restenosis. Circulation, 2002, 105, 1883-1886.	1.6	188
28	Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 13, 1540-1553.	3.2	185
29	Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery. Circulation, 2007, 116, 158-162.	1.6	182
30	Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention, 2016, 12, 38-46.	3.2	181
31	Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices. Journal of the American College of Cardiology, 2013, 61, 830-836.	2.8	176
32	A Bicuspid Aortic Valve Imaging ClassificationÂforÂthe TAVR Era. JACC: Cardiovascular Imaging, 2016, 9, 1145-1158.	5.3	174
33	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. American Heart Journal, 2008, 155, 274-283.	2.7	170
34	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
35	Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent Implantation. Circulation, 2003, 107, 2178-2180.	1.6	168
36	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet, The, 2021, 397, 199-207.	13.7	164

#	Article	IF	Citations
37	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2212-2219.	2.8	160
38	Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club. EuroIntervention, 2021, 16, 1307-1317.	3.2	147
39	Treatment of saphenous vein graft lesions with drug-eluting stents. Journal of the American College of Cardiology, 2005, 45, 989-994.	2.8	142
40	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11â€‰473 patients. European Heart Journal, 2017, 38, ehw627.	2.2	138
41	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136
42	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal, 2021, 42, 967-984.	2.2	136
43	Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. European Heart Journal, 2005, 26, 1056-1062.	2.2	133
44	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
45	Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. Journal of the American College of Cardiology, 2000, 35, 214-221.	2.8	129
46	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
47	Predictors of moderateâ€toâ€severe paravalvular aortic regurgitation immediately after corevalve implantation and the impact of postdilatation. Catheterization and Cardiovascular Interventions, 2011, 78, 432-443.	1.7	125
48	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
49	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
50	The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). European Heart Journal, 2021, 42, 3829-3839.	2.2	119
51	Comparison of Incidence and Predictors of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Using the CoreValve Versus the Edwards Valve. American Journal of Cardiology, 2013, 112, 554-559.	1.6	118
52	Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: Insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.7	113
53	Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity scoreâ€“matched case-control study. American Heart Journal, 2012, 164, 910-917.	2.7	111
54	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology, 2017, 69, 2011-2022.	2.8	109

#	Article	IF	Citations
55	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thrombosis and Haemostasis, 2019, 119, 149-162.	3.4	107
56	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. European Heart Journal, 2020, 41, 1839-1851.	2.2	106
57	Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Isletâ€"Transplanted Rats. Circulation, 2001, 103, 2980-2986.	1.6	104
58	Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. American Journal of Cardiology, 2004, 93, 213-216.	1.6	103
59	Multiple Overlapping Drug-Eluting Stents to Treat Diffuse Disease of the Left Anterior Descending Coronary Artery. Journal of the American College of Cardiology, 2005, 45, 1570-1573.	2.8	103
60	The EBC TWO Study (European Bifurcation Coronary TWO). Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	102
61	Consensus from the 7th European Bifurcation Club meeting. EuroIntervention, 2013, 9, 36-45.	3.2	102
62	Current management of left main coronary artery disease. European Heart Journal, 2012, 33, 36-50.	2.2	100
63	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. European Heart Journal, 2008, 29, 2108-2115.	2.2	99
64	Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. Journal of the American College of Cardiology, 2004, 44, 967-971.	2.8	97
65	Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 14, 112-120.	3.2	94
66	Drug-Eluting Stent Restenosis. Journal of the American College of Cardiology, 2006, 47, 2399-2404.	2.8	92
67	Incidence, Management, and Outcomes of Cardiac Tamponade During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1264-1272.	2.9	91
68	Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). European Heart Journal, 2018, 39, 676-684.	2.2	91
69	Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantationâ€. European Heart Journal, 2006, 27, 540-546.	2.2	89
70	Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents. Circulation, 2004, 109, 2732-2736.	1.6	88
71	Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. Journal of the American College of Cardiology, 2004, 43, 1154-1160.	2.8	88
72	Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheterization and Cardiovascular Interventions, 2006, 67, 175-180.	1.7	88

#	Article	IF	Citations
73	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation. JACC: Cardiovascular Interventions, 2008, 1, 56-61.	2.9	85
74	Acute and 30-Day Outcomes in WomenÂAfter TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	2.9	85
75	Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002025.	3.9	80
76	The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIENâ„¢ and Medtronic CoreValve ReValving SystemÂ® devices: the Milan registry. EuroIntervention, 2011, 7, 556-563.	3.2	80
77	Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. American Heart Journal, 2007, 153, 354-359.	2.7	79
78	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Severely Stenotic Bicuspid Versus Tricuspid or Nonbicuspid Valves. American Journal of Cardiology, 2014, 113, 1390-1393.	1.6	79
79	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. EuroIntervention, 2009, 5, 370-374.	3.2	78
80	Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: A Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. American Heart Journal, 2013, 165, 752-760.	2.7	77
81	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1-12.	2.9	77
82	Predictors of Advanced Conduction Disturbances Requiring a Late (â‰¥48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1519-1526.	2.9	77
83	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
84	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. International Journal of Cardiology, 2013, 168, 1402-1409.	1.7	73
85	Heyde's Syndrome Incidence and Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 61, 687-689.	2.8	73
86	Progression Rate of Ascending Aortic Dilation in Patients With Normally Functioning Bicuspid and Tricuspid Aortic Valves. American Journal of Cardiology, 2006, 98, 249-253.	1.6	72
87	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
88	Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. American Heart Journal, 2006, 152, 565-572.	2.7	69
89	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66
90	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102â€‰735 patients. European Heart Journal, 2017, 38, 3160-3172.	2.2	66

#	Article	IF	Citations
91	Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. Annals of Thoracic Surgery, 2014, 97, 22-28.	1.3	64
92	A Practical Approach to the ManagementÂof Complications During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1797-1810.	2.9	64
93	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62
94	SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. Catheterization and Cardiovascular Interventions, 2011, 77, 232-241.	1.7	62
95	Late Restenosis Following Sirolimus-Eluting Stent Implantation. American Journal of Cardiology, 2007, 100, 41-44.	1.6	60
96	In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. American Journal of Cardiology, 2005, 95, 757-760.	1.6	59
97	Effect of Body Mass Index on Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 111, 231-236.	1.6	58
98	Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. EuroIntervention, 2017, 12, 1730-1737.	3.2	58
99	Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2016, 117, 1714-1723.	1.6	57
100	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. Catheterization and Cardiovascular Interventions, 2020, 96, 1067-1079.	1.7	57
101	The occupational effects of interventional cardiology: results from the WIN for Safety survey. EuroIntervention, 2012, 8, 658-663.	3.2	57
102	Drug-Eluting Stent Update 2007. Circulation, 2007, 116, 1424-1432.	1.6	56
103	A novel approach to chronic total occlusions: The crosser system. Catheterization and Cardiovascular Interventions, 2006, 68, 29-35.	1.7	54
104	Long-Term Follow-Up on a Large Cohort of â€œFull-Metal Jacketâ€•Percutaneous Coronary Intervention Procedures. Circulation: Cardiovascular Interventions, 2009, 2, 416-422.	3.9	54
105	Histopathology of Clinical Coronary Restenosis in Drug-Eluting Versus Bare Metal Stents. American Journal of Cardiology, 2009, 104, 1660-1667.	1.6	54
106	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
107	Stent Thrombosis: Incidence, Predictors and New Technologies. Thrombosis, 2012, 2012, 1-12.	1.4	53
108	Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheterization and Cardiovascular Interventions, 2015, 85, E10-E15.	1.7	53

#	Article	IF	Citations
109	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	2.9	51
110	Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry. EuroIntervention, 2020, 15, e1343-e1350.	3.2	51
111	Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Drug-Eluting Stents. Journal of the American College of Cardiology, 2009, 54, 1131-1136.	2.8	50
112	Trends in outcome after transfemoral transcatheter aortic valve implantation. American Heart Journal, 2013, 165, 183-192.	2.7	49
113	Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice. Journal of the American College of Cardiology, 2007, 49, 2320-2328.	2.8	48
114	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ, The, 2016, 355, i5483.	6.0	48
115	Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis. International Journal of Cardiology, 2016, 211, 37-42.	1.7	48
116	Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI. International Journal of Cardiology, 2019, 293, 84-90.	1.7	46
117	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. Thrombosis Journal, 2009, 7, 4.	2.1	45
118	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. American Journal of Cardiology, 2010, 106, 1721-1727.	1.6	45
119	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45
120	Impact of Strut Width in Periprocedural Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 900-909.	2.9	44
121	Impact of Sirolimus-Eluting and Paclitaxel-Eluting Stents on Outcome in Patients With Diabetes Mellitus and Stenting in More Than One Coronary Artery. American Journal of Cardiology, 2006, 98, 362-366.	1.6	43
122	Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents forÂthe Management of Recurrent Multimetal-Layered In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 1586-1594.	2.9	43
123	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ, The, 2016, 354, i4935.	6.0	43
124	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43
125	Clinical Outcome Following Aleatory Implantation of Paclitaxel-Eluting or Sirolimus-Eluting Stents in Complex Coronary Lesions. American Journal of Cardiology, 2005, 96, 1663-1668.	1.6	42
126	Coronary Sinus Reducer Implantation forÂthe Treatment of Chronic RefractoryÂAngina. JACC: Cardiovascular Interventions, 2018, 11, 784-792.	2.9	42

#	Article	IF	Citations
127	The Role of Drug-Eluting Balloons Alone or in Combination With Drug-Eluting Stents in the Treatment of De Novo Diffuse Coronary Disease. JACC: Cardiovascular Interventions, 2013, 6, 1153-1159.	2.9	41
128	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
129	Validation of Predictors of Intraprocedural Stent Thrombosis in the Drug-Eluting Stent Era. American Journal of Cardiology, 2005, 95, 1466-1468.	1.6	40
130	Preliminary experience with the frontrunner coronary catheter: Novel device dedicated to mechanical revascularization of chronic total occlusions. Catheterization and Cardiovascular Interventions, 2005, 64, 146-152.	1.7	40
131	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. Circulation: Cardiovascular Interventions, 2020, 13, e008325.	3.9	39
132	Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2016, 118, 107-112.	1.6	38
133	Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	38
134	Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 570-583.	1.0	38
135	Impact of permanent pacemaker on mortality after transcatheter aortic valve implantation: the PRAGMATIC (Pooled Rotterdam-Milan-Toulouse in Collaboration) Pacemaker substudy. EuroIntervention, 2016, 12, 1185-1193.	3.2	38
136	Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drugâ€eluting stents in patients with myocardial infarction. Catheterization and Cardiovascular Interventions, 2009, 73, 15-21.	1.7	37
137	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention WithÂStents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	2.9	37
138	The European Bifurcation Club Left Main Study (EBC MAIN): rationale and design of an international, multicentre, randomised comparison of two stent strategies for the treatment of left main coronary bifurcation disease. EuroIntervention, 2016, 12, 47-52.	3.2	37
139	SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. EuroIntervention, 2011, 6, 866-874.	3.2	37
140	Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. Journal of the American College of Cardiology, 2005, 45, 805-806.	2.8	36
141	Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 119, 1088-1093.	1.6	36
142	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	2.8	36
143	Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. American Journal of Cardiology, 2016, 118, 1460-1465.	1.6	34
144	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33

#	Article	IF	Citations
145	First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1901-1903.	2.9	33
146	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
147	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	1.7	33
148	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 632 Td (No Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
149	Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). European Journal of Cardio-thoracic Surgery, 2016, 50, 1139-1148.	1.4	32
150	Correlates and Impact of Coronary ArteryÂCalcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
151	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	32
152	Effect of Chronic Kidney Disease in WomenÂUndergoing Percutaneous CoronaryÂIntervention With Drug-ElutingÂStents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
153	Evaluation of intermediate coronary stenosis with intravascular ultrasound and fractional flow reserve: Its use and abuse. Catheterization and Cardiovascular Interventions, 2009, 73, 441-448.	1.7	30
154	A â€œmodified crossover techniqueâ€•for vascular access management in highâ€risk patients undergoing transfemoral transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2013, 81, 579-583.	1.7	30
155	A comparison of the femoral and radial crossover techniques for vascular access management in transcatheter aortic valve implantation: The milan experience. Catheterization and Cardiovascular Interventions, 2014, 83, 156-161.	1.7	30
156	Italian Society of Interventional Cardiology (GISE) position paper for Cath labâ€specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID â€19. Catheterization and Cardiovascular Interventions, 2020, 96, 839-843.	1.7	30
157	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	2.9	30
158	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. Circulation: Cardiovascular Interventions, 2012, 5, 491-498.	3.9	29
159	Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 119, 1438-1442.	1.6	29
160	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1219-1226.	2.9	28
161	Balancing the Risk of Bleeding and Stroke in Patients WithÂAtrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	1.6	28
162	Effects of Body Mass Index on ClinicalÂOutcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 68-76.	2.9	28

#	Article	IF	Citations
163	Are we ready for a gender-specific approach in interventional cardiology?. International Journal of Cardiology, 2019, 286, 226-233.	1.7	28
164	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. Journal of Immunology, 2009, 183, 2537-2544.	0.8	27
165	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
166	Impact of Mixed Aortic Valve Stenosis on <scp>VARC</scp>â€2 Outcomes and Postprocedural Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation. Catheterization and Cardiovascular Interventions, 2015, 86, 875-885.	1.7	27
167	Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. American Journal of Cardiology, 2007, 99, 916-920.	1.6	26
168	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for LefT main) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.6	26
169	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
170	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. EuroIntervention, 2013, 9, 809-816.	3.2	26
171	17-Beta-Estradiol Eluting Stent Versus Phosphorylcholine-Coated Stent for the Treatment of Native Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 664-667.	1.6	25
172	Early Outcome of Treatment of Ostial De Novo Left Anterior Descending Coronary Artery Lesions With Drug-Eluting Stents. American Journal of Cardiology, 2006, 97, 187-191.	1.6	25
173	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. American Heart Journal, 2008, 156, 745-750.	2.7	25
174	Successful Percutaneous Anterograde Transcatheter Valve-in-Valve Implantation in the Mitral Position. JACC: Cardiovascular Interventions, 2011, 4, 1246-1247.	2.9	25
175	Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy. Catheterization and Cardiovascular Interventions, 2015, 86, 644-652.	1.7	25
176	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	6.1	25
177	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 338-343.	1.3	25
178	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	2.8	25
179	Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis. American Journal of Cardiology, 2006, 97, 1182-1187.	1.6	24
180	Clinical outcome and quality of life in octogenarians following transcatheter aortic valve implantation (TAVI) for symptomatic aortic stenosis. International Journal of Cardiology, 2013, 168, 281-286.	1.7	24

#	Article	IF	Citations
181	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
182	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	3.9	24
183	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 1477-1481.	1.6	23
184	Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. International Journal of Cardiology, 2019, 290, 59-63.	1.7	23
185	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. EuroIntervention, 2016, 11, 1355-1362.	3.2	23
186	Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: Insights from the TRUE (Taxusâ„¢ in Real-life Usage Evaluation) Study. International Journal of Cardiology, 2006, 108, 406-407.	1.7	22
187	The Long-Term Clinical Outcome of T-Stenting and Small Protrusion Technique for Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 554-561.	2.9	22
188	Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 International Journal of Cardiology, 2016, 207, 168-176.	1.7	22
189	Impact of Mitral Annular Calcium on Outcomes after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 2233-2240.	1.6	22
190	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	2.9	22
191	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	1.7	22
192	Percutaneous Transcatheter Aortic Valve Implantation. Cardiology in Review, 2010, 18, 111-124.	1.4	21
193	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21
194	First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. Cardiovascular Revascularization Medicine, 2013, 14, 311-315.	0.8	21
195	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clinical Research in Cardiology, 2019, 108, 643-650.	3.3	21
196	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	3.9	21
197	Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative. EuroIntervention, 2010, 5, 773-779.	3.2	21
198	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	3.2	21

#	Article	IF	Citations
199	Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. American Journal of Cardiology, 2004, 94, 1297-1300.	1.6	20
200	Comparison of First- and Second-Generation Drug-Eluting Stents in Saphenous Vein Grafts Used as Aorto-Coronary Conduits. American Journal of Cardiology, 2013, 112, 318-322.	1.6	20
201	Usefulness of Baseline Activated Clotting Timeâ€"Guided Heparin Administration in Reducing Bleeding Events During Transfemoral Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2014, 7, 140-151.	2.9	20
202	Drugâ€Eluting Balloon in the Treatment of Inâ€Stent Restenosis and Diffuse Coronary Artery Disease: Realâ€World Experience from Our Registry. Journal of Interventional Cardiology, 2014, 27, 348-355.	1.2	20
203	Long-Term (â‰¥10ÂYears) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. American Journal of Cardiology, 2016, 118, 32-39.	1.6	20
204	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	20
205	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). American Journal of Cardiology, 2019, 123, 1610-1619.	1.6	20
206	Angiographic Analysis of Pattern of Late Luminal Loss in Sirolimus- and Paclitaxel-Eluting Stents. American Journal of Cardiology, 2007, 99, 593-598.	1.6	19
207	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. American Journal of Cardiology, 2011, 108, 1055-1060.	1.6	19
208	The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: Correlation with fractional flow reserve. Cardiovascular Revascularization Medicine, 2014, 15, 3-7.	0.8	19
209	Impact of gender on long-term mortality in patients with unprotected left main disease: The Milan and New-Tokyo (MITO) Registry. Cardiovascular Revascularization Medicine, 2016, 17, 369-374.	0.8	19
210	Comparison Between 1- and 2-Stent Strategies in Unprotected Distal Left Main Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	19
211	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	1.6	19
212	The importance of achieving sex- and gender-based equity in clinical trials: a call to action. European Heart Journal, 2021, 42, 2990-2994.	2.2	19
213	ACS and STEMI treatment: gender-related issues. EuroIntervention, 2012, 8, P27-P35.	3.2	19
214	Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. EuroIntervention, 2016, 11, 989-995.	3.2	19
215	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. EuroIntervention, 2020, 16, 233-246.	3.2	19
216	Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. American Journal of Cardiology, 2004, 94, 351-354.	1.6	18

#	Article	IF	Citations
217	Polymer-Based Paclitaxel-Eluting Coronary Stents. Herz, 2004, 29, 147-151.	1.1	18
218	Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. American Heart Journal, 2005, 150, 807-813.	2.7	18
219	Recognition and management of complications during transcatheter aortic valve implantation. Expert Review of Cardiovascular Therapy, 2011, 9, 913-926.	1.5	18
220	Managing Patients With an Indication for Anticoagulant TherapyÂAfter Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 111, 237-242.	1.6	18
221	The impact of main branch restenosis on long term mortality following drugâ€eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 84, 341-348.	1.7	18
222	Dual Antiplatelet Therapy after Drug-Eluting Stents â€" How Long to Treat?. New England Journal of Medicine, 2014, 371, 2225-2226.	27.0	18
223	Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI?. International Journal of Cardiology, 2017, 233, 52-60.	1.7	18
224	Shortâ€versus longâ€term Dual Antiplatelet therapy after drugâ€eluting stent implantation in women versus men: A sexâ€specific patientâ€level pooledâ€analysis of six randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 178-189.	1.7	18
225	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2018, 122, 1909-1916.	1.6	18
226	Genderâ€based issues in interventional cardiology: A consensus statement from the Women in Innovations (WIN) Initiative. Catheterization and Cardiovascular Interventions, 2010, 75, 145-152.	1.7	17
227	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
228	â€œProcedural trauma risks longitudinal shortening of the promus elementâ„¢ stent platformâ€• Catheterization and Cardiovascular Interventions, 2013, 81, 810-817.	1.7	17
229	Feasibility of ultra-low contrast 64-slice computed tomography angiography before transcatheter aortic valve implantation: a real-world experience. European Heart Journal Cardiovascular Imaging, 2015, 17, jev175.	1.2	17
230	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and RiskÂfor Adverse EventsÂAmong Patients With and WithoutÂDiabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 645-654.	2.9	17
231	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	3.9	17
232	Longâ€term followâ€up of covered stent implantation for various coronary artery diseases. Catheterization and Cardiovascular Interventions, 2019, 94, 571-577.	1.7	17
233	Impella RP support in refractory right ventricular failure complicating acute myocardial infarction with unsuccessful right coronary artery revascularization. International Journal of Cardiology, 2020, 302, 135-137.	1.7	17
234	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WINâ€TAVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 97, 516-526.	1.7	17

#	Article	IF	Citations
235	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
236	Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 396-400.	3.3	16
237	Longâ€term clinical outcomes following drugâ€eluting stent implantation for unprotected distal trifurcation left main disease: The Milanâ€New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 83, 530-538.	1.7	16
238	Bioresorbable Scaffolds for theÂManagement of Coronary BifurcationÂLesions. JACC: Cardiovascular Interventions, 2016, 9, 989-1000.	2.9	16
239	Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). American Journal of Cardiology, 2016, 117, 813-819.	1.6	16
240	Clinical relevance of ticagrelor monotherapy following 1â€month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, 100-111.	1.7	16
241	Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 999-1006.	1.0	16
242	Treatment of iatrogenic occlusive coronary dissections: a novel approach. EuroIntervention, 2011, 7, 106-111.	3.2	16
243	Treatment of drugâ€eluting stent restenosis: Comparison between drugâ€eluting balloon versus secondâ€generation drugâ€eluting stents from a retrospective observational study. Catheterization and Cardiovascular Interventions, 2016, 88, 522-528.	1.7	15
244	Comparison between functional and intravascular imaging approaches guiding percutaneous coronary intervention: A network metaâ€analysis of randomized and propensity matching studies. Catheterization and Cardiovascular Interventions, 2020, 95, 1259-1266.	1.7	15
245	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. Catheterization and Cardiovascular Interventions, 2020, 96, 1-9.	1.7	15
246	Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-RotterdAm-Milano-Toulouse In Collaboration Aortic Stenosis survey. EuroIntervention, 2016, 11, e1305-e1313.	3.2	15
247	Percutaneous valve replacement in a young adult for radiation-induced aortic stenosis. Journal of Cardiovascular Medicine, 2012, 13, 397-398.	1.5	14
248	Impact of Mean Platelet Volume on Combined Safety Endpoint and Vascular and Bleeding Complications following Percutaneous Transfemoral Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-8.	1.9	14
249	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq1 1 0.784314 rgBT /Ove Cardiology, 2014, 113, 1348-1355.	1.6	14
250	Mid-term clinical outcomes after bailout drug-eluting stenting for suboptimal drug-coated balloon results: Insights from a Milan registry. International Journal of Cardiology, 2018, 263, 17-23.	1.7	14
251	Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study. International Journal of Cardiology, 2018, 250, 80-85.	1.7	14
252	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14

#	Article	IF	Citations
253	Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?. Catheterization and Cardiovascular Interventions, 2005, 64, 129-133.	1.7	13
254	The ratio of contrast volume to glomerular filtration rate predicts acute kidney injury and mortality after transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2017, 18, 349-355.	0.8	13
255	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	1.7	13
256	Interatrial Septal Tear After PatentÂForamen Ovale Closure WithÂtheÂNobleStitch Device. JACC: Cardiovascular Interventions, 2019, 12, e139-e140.	2.9	13
257	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAin or) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	13
258	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WINâ€TAVI) registry. Catheterization and Cardiovascular Interventions, 2020, 96, 198-207.	1.7	13
259	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. EuroIntervention, 2018, 14, e1227-e1235.	3.2	13
260	SCAI Consensus Document on Occupational Radiation Exposure to the Pregnant Cardiologist and Technical Personnel. Heart Lung and Circulation, 2011, 20, 83-90.	0.4	12
261	Singleâ€stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery. Catheterization and Cardiovascular Interventions, 2013, 82, 757-764.	1.7	12
262	Red blood cell distribution width predicts one-year mortality following transcatheter aortic valve implantation. International Journal of Cardiology, 2014, 172, 456-457.	1.7	12
263	Influence of baseline ejection fraction on the prognostic value of paravalvular leak after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 190, 277-281.	1.7	12
264	Impact of post-procedural hyperglycemia on acute kidney injury after transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 221, 892-897.	1.7	12
265	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	3.9	12
266	Radial Versus Femoral Access for the Treatment of LeftÂMain Lesion in the Era of Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2017, 120, 33-39.	1.6	12
267	Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients â€“ results from the BELLO (balloon elution and late loss) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	12
268	Prognostic Significance of Change in the Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Left Ventricular Dysfunction. American Journal of Cardiology, 2017, 120, 1639-1647.	1.6	12
269	Analysis of a Low Dose Protocol to Reduce Patient Radiation Exposure During Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 119, 203-209.	1.6	12
270	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	2.9	12

#	Article	IF	Citations
271	Revascularization Options for Females With Multivessel Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1009-1010.	2.9	12
272	Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.7	12
273	Predictive ability of the CHADS₂and CHA₂DS₂-VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 867-873.	1.4	11
274	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	1.7	11
275	Longâ€term outcomes following miniâ€crush versus culotte stenting for the treatment of unprotected left main disease: Insights from the milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2017, 89, 13-24.	1.7	11
276	CRosser As First choice for crossing Totally occluded coronary arteries (CRAFT Registry): focus on conventional angiography and computed tomography angiography predictors of success. EuroIntervention, 2011, 7, 480-486.	3.2	11
277	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	2.8	11
278	Creatine kinase-myocardial band isoenzyme elevation after percutaneous coronary interventions using sirolimus-eluting stents. American Journal of Cardiology, 2004, 93, 1397-1401.	1.6	10
279	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. Cardiovascular Revascularization Medicine, 2011, 12, 220-227.	0.8	10
280	Resultados a muy largo plazo tras la implantaciÃ³n de stents liberadores de fÃ¡rmacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. Revista Espanola De Cardiologia, 2013, 66, 24-33.	1.2	10
281	Drug-eluting stent outcomes in diabetes. Expert Review of Cardiovascular Therapy, 2014, 12, 95-109.	1.5	10
282	Early Outcomes With Direct Flow Medical Versus Firstâ€Generation Transcatheter Aortic Valve Devices: A Singleâ€Center Propensityâ€Matched Analysis. Journal of Interventional Cardiology, 2015, 28, 583-593.	1.2	10
283	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 1 0.784314 rgBT /Ov 2017, 120, 904-910.	1.6	10
284	Incidence of Adverse Events at 3 Months Versus at 12ÂMonths After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 2020, 125, 491-499.	1.6	10
285	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
286	Renal function and drug-eluting stent. International Journal of Cardiology, 2010, 142, 92-94.	1.7	9
287	Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated. International Journal of Cardiology, 2013, 168, 3791-3796.	1.7	9
288	Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women. Coronary Artery Disease, 2016, 27, 442-448.	0.7	9

#	Article	IF	Citations
289	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <scp>STATIPLAT</scp> randomized study. Clinical Cardiology, 2017, 40, 605-611.	1.8	9
290	Transapical aortic valve replacement is a safe option in patients with poor left ventricular ejection fraction: results from the Italian Transcatheter Balloon-Expandable Registry (ITER)â€. European Journal of Cardio-thoracic Surgery, 2017, 52, 874-880.	1.4	9
291	Definite stent thrombosis after drugâ€eluting stent implantation in coronary bifurcation lesions: A metaâ€analysis of 3,107 patients from 14 randomized trials. Catheterization and Cardiovascular Interventions, 2018, 92, 680-691.	1.7	9
292	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	1.6	9
293	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	1.6	9
294	Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention, 2021, 16, 1177-1186.	3.2	9
295	Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT). EuroIntervention, 2008, 4, 77-83.	3.2	9
296	Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study. EuroIntervention, 2014, 10, 916-923.	3.2	9
297	Comparison of abluminal biodegradable polymer biolimusâ€eluting stents and durable polymer everolimusâ€eluting stents in the treatment of coronary bifurcations. Catheterization and Cardiovascular Interventions, 2014, 83, 889-895.	1.7	8
298	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. International Journal of Cardiology, 2014, 177, 11-16.	1.7	8
299	First generation versus new generation drugâ€eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2015, 85, E63-9.	1.7	8
300	Clinical outcomes following bifurcation doubleâ€stenting with bioresorbable scaffolds. Catheterization and Cardiovascular Interventions, 2016, 88, 854-862.	1.7	8
301	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	1.7	8
302	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. EuroIntervention, 2020, 16, e133-e140.	3.2	8
303	Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. Vascular Health and Risk Management, 2007, 3, 441-51.	2.3	8
304	Cuestiones relativas al sexo en cardiologÃa intervencionista: declaraciÃ³n de consenso de la iniciativa Women in Innovations (WIN). Revista Espanola De Cardiologia, 2010, 63, 200-208.	1.2	7
305	Acute Stent Recoil From Aggressive Post-Dilation of a Second-Generation Drug-Eluting Stent. JACC: Cardiovascular Interventions, 2013, 6, 311-313.	2.9	7
306	Transcatheter aortic valve implantation in intermediate- and low-risk populations: An inevitable progression?. International Journal of Cardiology, 2016, 210, 35-37.	1.7	7

#	Article	IF	Citations
307	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. International Journal of Cardiology, 2017, 246, 26-31.	1.7	7
308	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Canadian Journal of Cardiology, 2019, 35, 199-207.	1.7	7
309	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004945.	2.2	7
310	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	1.7	7
311	Sex and Transcatheter Aortic Valve Implantation: Impact of Female Sex on Clinical Outcomes. Interventional Cardiology Review, 2019, 14, 137-141.	1.6	7
312	Prolonged Double Antiplatelet Therapy in a Cohort of â€œDe Novoâ€•Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
313	Left Main Thrombotic Occlusion Following Balloon Aortic Valvuloplasty for Severe Aortic Stenosis. Canadian Journal of Cardiology, 2012, 28, 759.e13-759.e15.	1.7	6
314	Tardive Coronary Obstruction By a Native Leaflet After Transcatheter Aortic Valve Replacement in a Patient With Heavily Calcified Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2014, 7, e105-e107.	2.9	6
315	Impact of renal dysfunction on long-term mortality in patients with unprotected left main disease: Milan and New-Tokyo (MITO) Registry. International Journal of Cardiology, 2014, 177, 1131-1133.	1.7	6
316	Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure. Catheterization and Cardiovascular Interventions, 2016, 87, 832-836.	1.7	6
317	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
318	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	3.9	6
319	Residual angina in female patients after coronary revascularization. International Journal of Cardiology, 2019, 286, 208-213.	1.7	6
320	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. Catheterization and Cardiovascular Interventions, 2021, 97, E227-E236.	1.7	6
321	Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 881-891.	4.0	6
322	Initial experience with a new 8 French-compatible directional atherectomy catheter: Immediate and mid-term results. Catheterization and Cardiovascular Interventions, 2003, 60, 159-166.	1.7	5
323	Response to Letters Regarding Article, â€œPercutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis: A Single-Center Experienceâ€• Circulation, 2006, 114, .	1.6	5
324	ElecciÃ³n de intervenciÃ³n coronaria percutÃ¡nea o bypass en la enfermedad coronaria multivaso. Revista Espanola De Cardiologia, 2014, 67, 428-431.	1.2	5

#	Article	IF	Citations
325	Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation. Catheterization and Cardiovascular Interventions, 2016, 88, 865-870.	1.7	5
326	Five-year evolution of mild aortic regurgitation following transcatheter aortic valve implantation: early insights from a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 75-82.	1.1	5
327	Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound. Catheterization and Cardiovascular Interventions, 2017, 89, 789-797.	1.7	5
328	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	5
329	T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models. Cardiovascular Revascularization Medicine, 2021, 24, 11-17.	0.8	5
330	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	3.7	5
331	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	3.2	5
332	Is There Still a Survival Advantage to Bypass Surgery Over Percutaneous Intervention in the Modern Era?. Progress in Cardiovascular Diseases, 2015, 58, 335-341.	3.1	4
333	T-Stenting With SmallÂProtrusion. JACC: Cardiovascular Interventions, 2016, 9, 1853-1854.	2.9	4
334	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	1.7	4
335	Gender Issues in Italian Catheterization Laboratories: The Genderâ€CATH Study. Journal of the American Heart Association, 2021, 10, e017537.	3.7	4
336	The importance of proximal optimization technique with intravascular imaging guided for stenting unprotected left main distal bifurcation lesions: The Milan and Newâ€Tokyo registry. Catheterization and Cardiovascular Interventions, 2021, 98, E814-E822.	1.7	4
337	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	1.6	4
338	A New Tool to Manage Side-Branch Occlusion After Covered-Stent Implantation for Vascular Complications. JACC: Cardiovascular Interventions, 2013, 6, 893-894.	2.9	3
339	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. Revista Espanola De Cardiologia (English Ed), 2013, 66, 24-33.	0.6	3
340	A comparison of the fully repositionable and retrievable B oston L otus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience. Catheterization and Cardiovascular Interventions, 2018, 91, 966-974.	1.7	3
341	New-Generation Drug-Eluting Stents forÂLeft Main In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 2438-2440.	2.9	3
342	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	1.7	3

#	Article	IF	Citations
343	Impact of the metal-to-artery ratio on clinical outcomes in left main and nonleft main bifurcation: insights the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or bifurcatioN) Tj ETQq1 1 0.784314 rgBT /Ov	1.7	3
344	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	1.7	3
345	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. Cardiovascular Revascularization Medicine, 2022, 35, 66-73.	0.8	3
346	Elective Double Stenting for Left Main Coronary Artery Bifurcation Lesions. , 2010, , 149-192.		3
347	Clinical impact of bifurcation angle change between diastole and systole in complex stenting for left main distal bifurcation: The Milan and Newâ€Tokyo (MITO) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E24-E34.	1.7	3
348	Safety and feasibility of Bivalirudin with either Cypher and Taxus drug-eluting stent during percutaneous coronary intervention. EuroIntervention, 2005, 1, 70-4.	3.2	3
349	Transcatheter Aortic Bioprosthesis Durability: A Single-Center Experience. Cardiovascular Revascularization Medicine, 2022, 43, 1-6.	0.8	3
350	Beta-radiation therapy for long lesions in native coronary vessels. Cardiovascular Radiation Medicine, 2003, 4, 18-24.	0.6	2
351	Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?. Interventional Cardiology, 2015, 7, 35-54.	0.0	2
352	Dual antiplatelet therapy following drug-eluting stent implantation: how long is long enough?. Expert Review of Cardiovascular Therapy, 2015, 13, 585-587.	1.5	2
353	Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Journal of Cardiovascular Medicine, 2015, 16, 286-295.	1.5	2
354	Clinical outcomes following bioresorbable scaffold implantation in small vessels. International Journal of Cardiology, 2016, 207, 59-61.	1.7	2
355	Resource utilization for transfemoral transcatheter aortic valve replacement: An international comparison. Catheterization and Cardiovascular Interventions, 2016, 87, 145-151.	1.7	2
356	Bioresorbable Vascular Scaffolds and Very Late Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 745-746.	2.9	2
357	What the surgeon needs to know about percutaneous coronary intervention treatment of chronic total occlusions. Annals of Cardiothoracic Surgery, 2018, 7, 533-545.	1.7	2
358	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	3.4	2
359	Clinical outcomes of double stent strategy for unprotected left main distal bifurcation lesions using current generation drug eluting stent comparing to early generation drug eluting stent; The Milan and New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2021, 97, E198-E208.	1.7	2
360	Pericardium-covered stent: a reality for coronary interventions of the future?. Interventional Cardiology, 2012, 4, 411-418.	0.0	2

#	Article	IF	Citations
361	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	3.2	2
362	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
363	PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy. Platelets, 2014, 25, 337-342.	2.3	1
364	One Versus Two Stents. JACC: Cardiovascular Interventions, 2014, 7, 264-265.	2.9	1
365	Percutaneous treatment of left main disease: Still learning about the optimal PCI strategy. Cardiovascular Revascularization Medicine, 2016, 17, 494-496.	0.8	1
366	A challenging case of transcatheter aortic prosthesis dysfunction: Endocarditis or thrombosis?. International Journal of Cardiology, 2016, 214, 500-501.	1.7	1
367	Incidence and significance of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. International Journal of Cardiology, 2016, 222, 674-675.	1.7	1
368	Left Main Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 125-134.	0.4	1
369	Dual Antiplatelet Therapy After Bioresorbable VascularÂScaffold Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1471-1472.	2.9	1
370	Selfâ€expandable sirolimusâ€eluting stents compared to secondâ€generation drugâ€eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILSâ€2 registries. Catheterization and Cardiovascular Interventions, 2019, 93, 208-215.	1.7	1
371	Active Protection of High-Risk Small Side Branches in Bifurcation Interventions. JACC: Cardiovascular Interventions, 2020, 13, 1123-1125.	2.9	1
372	RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results. Circulation: Cardiovascular Interventions, 2021, 14, e010013.	3.9	1
373	Tools & Techniques: Left main coronary artery percutaneous coronary intervention. EuroIntervention, 2011, 6, 1020-1021.	3.2	1
374	Left Main Stem Disease. , 2014, , 1-16.		1
375	STEMIs and a Closer Look at MINOCA During the COVID-19 Pandemic. , 2022, , 100372.		1
376	Drug-eluting stents: What is the balance of risks and benefits?. Current Cardiovascular Risk Reports, 2007, 1, 279-283.	2.0	0
377	Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 92-93.	3.3	0
378	Rebuttal: Response to Dr. Morton Kern. Catheterization and Cardiovascular Interventions, 2009, 74, 814-814.	1.7	0

#	Article	IF	Citations
379	Stent Thrombosis After Kissing Balloons. JACC: Cardiovascular Interventions, 2012, 5, 1290-1291.	2.9	0
380	Diabetes and everolimus-eluting stents: what we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial. Expert Review of Cardiovascular Therapy, 2013, 11, 151-154.	1.5	0
381	Optimal Medical Treatment: Is It the Worst Option in Multivessel Coronary Disease? Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 1075.	0.6	0
382	Tratamiento mÃ©dico Ã³ptimo: Â¿es la peor opciÃ³n en la enfermedad coronaria multivaso? Respuesta. Revista Espanola De Cardiologia, 2014, 67, 1075.	1.2	0
383	Reply. Journal of the American College of Cardiology, 2015, 65, 2360-2361.	2.8	0
384	Transarterial Endoleak Closure After Endovascular Thoracoabdominal Aneurysm Repair. Journal of Endovascular Therapy, 2016, 23, 220-224.	1.5	0
385	The Unforgettable Cornerstone. Journal of the American College of Cardiology, 2017, 69, 755-756.	2.8	0
386	Percutaneous Transjugular Tricuspid Valve-In-Valve Implantation for Degenerated Surgical Bioprosthetic Valve. Cardiovascular Revascularization Medicine, 2020, 21, 808-809.	0.8	0
387	Percutaneous Unprotected Left Main Coronary Artery Interventions â€“ Updated Results and Current Recommendations. Interventional Cardiology Review, 2011, 6, 44.	1.6	0
388	How should I treat a left main spontaneous dissection involving left anterior descending artery, intermediate branch artery and left circumflex artery?. EuroIntervention, 2013, 9, 285-289.	3.2	0
389	Left Main Stem Disease. , 2015, , 2205-2217.		0
390	Technical Aspects of Left Main Stem Percutaneous Coronary Intervention. , 2015, , 237-253.		0
391	Bifurcations: Tips and Tricks. , 2016, , 215-219.		0
392	How long should dual antiplatelet therapy be continued following implantation of drug eluting stents?. Annals of Translational Medicine, 2015, 3, S10.	1.7	0
393	Post-stenting optimisation techniques in bifurcation percutaneous coronary interventions: much remains to be explored. EuroIntervention, 2021, 17, e869-e871.	3.2	0
394	The impact of chronic kidney disease severity on clinical outcomes after current generation drug-eluting stent implantation for left main distal bifurcation lesions: the Milan and New-Tokyo registry. Scandinavian Cardiovascular Journal, 2022, 56, 236-242.	1.2	0